RecruitingPhase 2NCT07670195

BCAAs in Concussion 3.0

HIT HEADS 3.0: Head Injury Treatment: A Randomized, Placebo-controlled, Double-blinded, Therapeutic Clinical Trial of Branched Chain Amino Acids (BCAAs) in the Treatment of Concussion


Sponsor

Akiva Cohen

Enrollment

150 participants

Start Date

Aug 5, 2026

Study Type

INTERVENTIONAL

Conditions

Summary

This study is a randomized, placebo-controlled, double-blinded, therapeutic exploratory clinical trial of branched chain amino acids (BCAAs) in the treatment of concussion. The aim of the study is to determine whether administration of high-dose BCAAs compared to placebo promotes concussion recovery.


Eligibility

Min Age: 11 YearsMax Age: 23 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called BCAA and Placebo for people with concussion, concussion (diagnosis), and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 11 Years to 23 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGBCAA

The three BCAAs will be combined together into a powder formulation.

OTHERPlacebo

The placebo formulation will have similar taste, texture, consistency and appearance as the BCAA formulation.


Locations(1)

Children's Hospital of Philadelphia

Havertown, Pennsylvania, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07670195


Related Trials